Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT00302029
Other study ID # 05-0126
Secondary ID
Status Terminated
Phase N/A
First received March 9, 2006
Last updated November 10, 2011
Start date June 2006
Est. completion date December 2008

Study information

Verified date November 2009
Source National Institute of Allergy and Infectious Diseases (NIAID)
Contact n/a
Is FDA regulated No
Health authority United States: Federal GovernmentUnited States: Institutional Review Board
Study type Observational

Clinical Trial Summary

The purpose of this study is to find out more about cytomegalovirus (CMV) and how it is spread between people. One thousand adolescent males ages 12-17 years will participate in this study. Participants will be given a questionnaire about risk factors for CMV. A small blood sample (2-3 teaspoons) will be taken to test for CMV infection. Subjects that are CMV seronegative may participate in the second part of this study, which will involve returning to the clinic at regularly scheduled visit times to provide blood, urine, and saliva (spit) samples. This part of the study will take at least 24 months to complete. Subjects that test positive for CMV during the 2nd portion of the study will be invited to participate in the 3rd part of the study. This part of the study will require 8 regularly scheduled visits to provide blood, urine and saliva samples, over a 12-month period. The maximum amount of time a subject will participate in the study is 36 months.


Description:

The objectives of this study are to: (1) to determine the prevalence of cytomegalovirus (CMV) infection and risk factors for infection in adolescent males; (2) to prospectively define the incidence and to evaluate risk factors for acquisition of CMV infection in adolescent males; and (3) to provide preliminary data on the duration and magnitude of CMV in the urine, saliva, and blood in those subjects who seroconvert during the study. Approximately 1000 males aged 12 to 17 years will be recruited from adolescent clinics at Cincinnati Children's Hospital Medical Center, Vanderbilt University, and the University of Texas Medical Branch at Galveston in order to obtain 225 CMV-seronegative subjects (75 at each site) to complete the Prospective Risk Factor Analysis. Patient participation will last a minimum of 24 months with 8 scheduled visits for the prospective seroepidemiology study. Patients who seroconvert will be invited to join the viral load analysis portion of the study, which consists of 8 scheduled visits during a 12 month period. The maximum duration of the study is 36 months, but will depend on the timing of seroconversion and entry into the viral load analysis. The study is divided into 3 parts: Seroprevalence, Prospective Risk Factor Analysis, and Prospective Viral Load Analysis. In the Seroprevalence portion of the study, after subjects have completed informed assent and parents or guardian consent, a small amount (10 mL) of blood will be obtained from subjects for evaluation of CMV antibody by commercial ELISA. Participants will be given a CMV fact sheet. Subjects will be contacted by phone with results of CMV antibody testing and the implications. They will be given the opportunity to receive the fact sheet again and discuss this information with study personnel, if they desire. Also at this visit, subjects who meet the eligibility criteria will be asked to complete a detailed questionnaire regarding possible risk factors for CMV infection. For those subjects 14 years of age and older, the questionnaire will include questions about sexual practices. Risk factors for CMV infection will then be compared between those subjects who are seropositive and those who are seronegative. Subjects who are CMV seronegative will be invited to participate in the Prospective Risk Factor Analysis portion of the study to determine the incidence of CMV infection and risk factors for acquisition in adolescent males. Eligible subjects will be identified and provided with a description of the study by a research nurse or study coordinator. Subjects will be asked to sign a separate assent and consent will be obtained from the parent or legal guardian. It is anticipated that recruitment will require approximately 1 year. Every 3 months, urine (For CMV culture and polymerase chain reactions [PCR]) and serum samples (for CMV antibody and PCR) will be collected from the subjects and analyzed for identification of CMV infection. In addition, subjects will complete a questionnaire evaluating risk factors at each 3-month visit. For those subjects who are 14 years of age or older, the questionnaire will include questions about sexual practices. If the subject tests positive for CMV, he will be asked to sign a separate consent to participate in the third phase of the study. In the Prospective Viral Load Analysis, subjects who seroconvert during the second portion of the study will be invited to participate in an evaluation of the duration and magnitude of CMV levels in blood, urine, and saliva. Subjects will be seen every month for 4 months followed by every 2 months for 8 months for collection of these specimens.


Recruitment information / eligibility

Status Terminated
Enrollment 411
Est. completion date December 2008
Est. primary completion date December 2008
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Male
Age group 12 Years to 17 Years
Eligibility Inclusion Criteria: 1. Subjects must be willing and able to provide written informed assent prior to enrollment, and parent(s) or legal guardian must provide written informed consent prior to study enrollment. 2. Subjects must be male and between 12 to 17 years of age at the time of initial study entry. 3. Subjects must be willing and able to comply with the requirements of the protocol and must be available for the 24-month duration of the study (for Prospective Risk Factor Analysis portion of the study only). 4. Subjects must be willing and able to comply with the requirements of the protocol and must be available for the 12-month duration of the study (for CMV Viral Load Analysis). Exclusion Criteria: 1. Receipt of blood and/or blood products in the past 3 months (Subjects meeting this exclusion criterion will also be excluded from the Seroprevalence study visit); 2. Unable to comply with the study protocol; 3. Infection with CMV prior to Seroprevalence study (for Prospective Risk Factor Analysis and CMV Viral Load Analysis portions of the study only); 4. History of any physical, mental or developmental disorder that study personnel believe may hinder a participant's ability to comply with study requirements (for Prospective Risk Factor Analysis and CMV Viral Load Analysis portions of the study only); 5. History of malignancy or having a confirmed or suspected immunodeficient condition such as HIV infection or receipt of immunosuppressive drugs. Inhaled and topical corticosteroids will be allowed (for Prospective Risk Factor Analysis and CMV Viral Load Analysis portions of the study only); 6. Receipt of or history of receipt of any medications or treatments that affect the immune system, such as immune globulin, interferon, immunomodulators, cytotoxic drugs, or other drugs known to be frequently associated with significant major organ toxicity or systemic steroids (oral or injectable) in the past 6 months (for Prospective Risk Factor Analysis and CMV Viral Load Analysis portions of the study only); 7. Prior receipt of a CMV vaccine.

Study Design

Observational Model: Cohort, Time Perspective: Prospective


Related Conditions & MeSH terms


Locations

Country Name City State
United States Cincinnati Children's Hospital Medical Center Cincinnati Ohio
United States The University of Texas Medical Branch Galveston Texas
United States Vanderbilt University Nashville Tennessee

Sponsors (1)

Lead Sponsor Collaborator
National Institute of Allergy and Infectious Diseases (NIAID)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Seroprevalence of CMV infection in adolescent boys Obtained every month for 4 months and then every 2 months for 8 months. No
Primary Prospectively determine the incidence of CMV infection. Day 0 and every 3 months for 24 months. No
Primary Determine the duration and magnitude of CMV replication in the blood, urine, and saliva by specimens. Obtained every month for 4 months and then every 2 months for 8 months. No
Secondary Prospectively identify risk factors for infection. Day 0 and every 3 months for 24 months. No
Secondary Identify risk factors for CMV infection by comparing those subjects who are CMV seropositive with those subjects who are CMV seronegative. Screening No
See also
  Status Clinical Trial Phase
Terminated NCT03950414 - A Dose-Escalation Study Evaluating Safety and Tolerability of Viral-Specific T Cells Against CMV in Adult Solid Organ Transplant Recipients Phase 1
Recruiting NCT04690933 - AntiCMV molécules Monitoring in Real-life in Stem Cell Recipients
Withdrawn NCT04936971 - Introduction of mTor Inhibitors and the Activation of the Cytomegalovirus (CMV) -Specific Cellular Immune Response Phase 4
Recruiting NCT02671318 - Conversion to Sirolimus: Effects in Cytomegalovirus Infection Recurrence Phase 4
Completed NCT01325636 - Injection of CD4 and CD8 + T Cells Anti-Cytomegalovirus (CMV) or Anti-adenovirus Phase 1/Phase 2
Recruiting NCT00228202 - Genotyping of Cytomegalovirus From Patients in Israel N/A
Completed NCT00031421 - Neonatal CMV-Ganciclovir Follow-up Study N/A
Completed NCT00005496 - Inflammation, Infection, and Future Cardiovascular Risk N/A
Terminated NCT03262194 - Relevance of Gastric Aspirate in HCMV Detection
Completed NCT04478474 - Cytomegalovirus (CMV) Viremia and Disease Occurrence in Pediatric Allogeneic Stem Cell Transplantation Recipients
Recruiting NCT05370976 - Efficacy and Safety of Cytotect®CP, Hyperimmune Anti-CMV IVIg as CMV Prophylaxis in Patients Developing Acute Grade II-IV GVHD After Allogeneic Hematopoietic Cell Transplantation. Phase 2
Active, not recruiting NCT02943057 - Topical 2% Ganciclovir Eye Drop for CMV Anterior Uveitis / Endotheliitis Phase 4
Completed NCT02538172 - Cell-mediated Immunity for Prevention of CMV Disease N/A
Completed NCT02642822 - The Epidemiologic Study of Human Cytomegalovirus(CMV) in Female Students of Xiamen University N/A
Completed NCT02134184 - The Influence of Chronic CMV Infection on Influenza Vaccine Responses Phase 4
Completed NCT00673868 - Cytomegalovirus (CMV) Specific Cytotoxic T Lymphocytes (CTL) When Used for Prophylaxis Against CMV in Recipients of Allogeneic, T Cell Depleted Stem Cell Transplants Phase 1
Active, not recruiting NCT05089630 - A Study of Safety and Immune Response to Different Doses of a Cytomegalovirus Vaccine in Healthy Adults Phase 1/Phase 2
Not yet recruiting NCT06058858 - Incidence and Risks Factors of CMV Reactivation in Patients Receiving of CAR-T Cells for Acute Leukemia and Lymphoma Relapse, a Cohort Study Analysis
Active, not recruiting NCT04904614 - Letermovir Use in Heart Transplant Recipients Phase 4
Completed NCT01986010 - Safety, Tolerability, and Immunogenicity of the Human Cytomegalovirus Vaccine (V160) in Healthy Adults (V160-001) Phase 1